Global human genetics of HIV-1 infection and China

Cell Research

Volumn 15, Issue 11-12, 2005, Pages 833-842

  Zhu, Tuo Fu ^a,b   Feng, Tie Jian ^c   Xiao, Xin ^d   Wang, Hui ^e   Zhou, Bo Ping ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d JINAN UNIVERSITY   (China)

^e Shenzhen Municipal Hospital of Infectious Diseases   (China)

Author keywords

China; Genetic polymorphisms; HIV

Indexed keywords

CHINA; GENETIC POLYMORPHISM; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

CHINA; HIV INFECTIONS; HIV-1; HUMANS; POLYMORPHISM, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 29244485439     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290355     Document Type: Review

References (138)

1. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8:1123-8.
2. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic, immunologic characterization of long-term survivors of HIV-1 infection. N Engl J Med 1995; 332:201-8.
3. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive HIV infection. New Eng J Med 1995; 332:209-16.
4. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270:988-91.
5. Rowland-Jones SL, Nixon DF, Aldhous MC, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993; 341:860-861.
6. De Maria A, Cirillo C, Moretta L. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J Infect Dis 1994; 170:1296-9.
7. Mayaux MJ, Blanche S, Rouzioux C, et al. Maternal factors associated with perinatal HIV-1 transmission: the French Cohort Study: 7 years of follow-up observation. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:188-94.
8. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, Oksenhendler E. Human immunodeficiency virus (HIV) nefspecific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest 1994; 93:1293-7.
9. Rowland-Jones SL, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64.
10. Mazzoli S, Trabattoni D, Lo Caputo S, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3:1250-7.
11. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multipleconserved HIV epitopes in HIV- resistant prostitutes in Nairobi. J Clin Invest 1998; 102:1758-65.
12. Rowland-Jones SL, Dong T, Dorrell L, et al. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly- exposed persistently seronegative donors. Immunol Lett 1999; 66:9-14.
13. Kaul R, Trabattoni D, Bwayo JJ, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Aids 1999; 13:23-9.
14. Kaul R, Plummer FA, Kimani J, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1- resistant prostitutes in Nairobi. J Immunol 2000; 164:1602-11.
15. Kaul R, Rowland-Jones SL, Kimani J, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre- existing HIV-specific CD8+ responses. J Clin Invest 2001; 107:341-9.
16. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. Aids 2001; 15:431-2.
17. Kaul R, Dong T, Plummer FA, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-10.
18. MacDonald KS, Fowke KR, Kimani J, et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181:1581-9.
19. Dorrell L, Hessell AJ, Wang M, et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. Aids 2000; 14:1117-22.
20. Devito C, Hinkula J, Kaul R, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. Aids 2000; 14:1917-20.
21. Sriwanthana B, Hodge T, Mastro TD, et al. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses 2001; 17:719-34.
22. Fowke KR, Kaul R, Rosenthal KL, et al. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 2000; 78:586-95.
23. Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 1995; 7:448-55.
24. Rowland-Jones SL, Pinheiro S, Kaul R, et al. How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol Lett 2001; 79:15-20.
25. Plummer FA, Ball TB, Kimani J, Fowke KR. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Immunol Lett 1999; 66:27-34.
26. Gibbons J, Cory JM, Hewlett IK, Epstein JS, Eyster ME. Silent infections with human immunodeficiency virus type 1 are highly unlikely in multitransfused seronegative hemophiliacs. Blood 1990; 76:1624-1626.
27. Lederman MM, Jackson JB, Kroner BL, et al. Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs. J Infect Dis 1995; 172:228-31.
28. Goh WC, Markee J, Akridge RE, et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179: 548-57.
29. Akridge R, Hladik F, Markee J, et al. Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure. Immunol Lett 1999; 66:15-9.
30. Schmechel SC, Russell N, Hladik F, et al. Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons. Immunol Lett 2001; 79:21-7.
31. Hladik F, Desbien A, Lang J, et al. Most highly exposed seronegative men lack HIV-1-specific, IFN-{gamma}-secreting T cells. J Immunol 2003; 171:2671-83.
32. Liu H, Hwangbo Y, Holte S, et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004; 190:1055-8.
33. Imagawa DT, Lee MH, Wolinsky SM, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989; 320: 1458-62.
34. Pinto LA, Sullivan J, Berzofsky JA, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995; 96:867-76.
35. Clerici M, Giorgi J, Chou C, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992; 165:1012-9.
36. Bernard NF, Yannakis CM, Lee JS, Tsoukas CM. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J Infect Dis 1999; 179:538-47.
37. Makedonas G, Bruneau J, Lin H, Sekaly RP, Lamothe F, Bernard NF. HIV-specific CD8 T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity. Aids 2002; 16:1595-602.
38. Mazzoli S, Lopalco L, Salvi A, et al. Human immunodeficiency virus (HIV)-specific IgA nd HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871-5.
39. Lopalco L, Pastori C, Cosma A, et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000; 16:109-115.
40. Devito C, Broliden K, Kaul R, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165: 5170-6.
41. Brown L, Souberbielle BE, Marriott JB, et al. The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people. Aids 1999; 13:2515-21.
42. Beretta A, Weiss SH, Rappocciolo G, et al. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis 1996; 173: 472-6.
43. Pinto LA, Sharpe S, Cohen DI, Shearer GM. Alloantigen-stimulated anti-HIV activity. Blood 1998; 92:3346-54.
44. Skurnick JH, Palumbo P, DeVico A, et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002; 185:428-38.
45. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
46. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-25.
47. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
48. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
49. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3:338-40.
50. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277:959-65.
51. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282:1907-11.
52. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999; 96:4581-5.
53. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. Aids 2000; 14:2671-8.
54. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1 alpha : Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A 2001; 98:5199-204.
55. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-95.
56. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000; 177:99-111.
57. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 1996; 272: 872-7.
58. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1 [see comments]. Nature 1996; 381:661-6.
59. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
60. Berger E, Doms R, Fenyö E, et al. A new classification for HIV-1. Nature 1998;391:240.
61. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8.
62. Connor RI, Paxton WA, Sheridan KE, Koup RA. Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. J Virol 1996; 70:8758-64.
63. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412-7.
64. Biti R, Ffrench R, Young J, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997; 3: 252-3.
65. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997; 349:1219-24.
66. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997; 349:1219-20.
67. Balotta C, Bagnarelli P, Violin M, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997; 11:F67-71.
68. Michael NL, Nelson JA, KewalRamani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998; 72:6040-7.
69. Edelstein RE, Arcuino LA, Hughes JP, et al. Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/delta32ccr5 heterozygotes. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:243-6.
70. Malo A, Rommel F, Bogner J, et al. Lack of protection from HIV infection by the mutant HIV coreceptor CCR5 in intravenously HIV infected hemophilia patients. Immunobiology 1998; 198:485-8.
71. Misrahi M, Teglas JP, N'Go N, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group Jama 1998; 279:277-80.
72. Shearer WT, Kalish LA, Zimmerman PA. CCR5 HIV-1 vertical transmission. Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:180-1.
73. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998; 4:786-93.
74. Hladik F, Liu H, Speelmon E, et al. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005; 79:11677-84.
75. Katzenstein TL, Eugen-Olsen J, Hofmann B, et al. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:10-4.
76. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3:23-36.
77. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-90.
78. Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305-310.
79. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non- progressors with HIV-1 infection. The Australian Long-Term Non- Progressor Study Group. AIDS 1997; 11:1833-8.
80. Paxton WA, Kang S and Koup RA. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses 1998; 14 Suppl 1:S89-92.
81. Rappaport J, Cho YY, Hendel H, Schwartz EJ, Schachter F, Zagury JF. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes [letter]. Lancet 1997; 349:922-3.
82. Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, Schuitemaker H. No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999; 179:825-31.
83. Wilkinson DA, Operskalski EA, Busch MP, Mosley JW, Koup RA. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis 1998; 178:1163-6.
84. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997; 16:100-3.
85. Libert F, Cochaux P, Beckman G, et al. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998; 7:399-406.
86. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-D32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998; 62:1507-15.
87. Wang FS, Hong WG, Cao Y, et al. Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF1 3'A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups. J Acquir Immune Defic Syndr 2003; 32:124-30.
88. Feng T, Ni A, Yang G, Galvin SR, Huffman IF, Cohen MS. Distribution of the CCR5 gene 32-base pair deletion and CCR5 expression in Chinese minorities. J Acquir Immune Defic Syndr 2003; 32:131-4.
89. Hong W, Wang F, Jin L, et al. Genotyping of HIV resistant alleles in indigenous Tibetan ethnic group of China: low frequency of CCR5triangle32 and high frequency of CCR2b-64I alleles. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18:268-71.
90. Zhang C, Fu S, Xue Y, et al. Distribution of the CCR5 gene 32-basepair deletion in 11 Chinese populations. Anthropol Anz 2002; 60:267-71.
91. Jiang JD, Wang Y, Wang ZZ, et al. Low frequency of the ccr5delta32 HIV-resistance allele in mainland China: identification of the first case of ccr5delta32 mutation in the Chinese population. Scand J Infect Dis 1999; 31:345-8.
92. Deng XL, Hong KX, Chen J-p, et al. Genetic polymorphisms of human immunodeficiency virus coreceptor CCR5 delta 32 and CCR2-64I alleles in Chinese Yi Ethnic group in Sichun. Chinese J Epidemiology 2004; 25:1050-3.
93. Wang XH, Feng TJ, Wang FS, et al. The effect of CCR delta32, CCR5m303, CCR2-64I and SDF1-3'A gene polymorphism to the prognosis of Chinese HIV-1 carriers. Chinese J Experimental Clinical Virology 2005; 19.
94. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352:866-70.
95. Li C, Lu SC, Hsieh PS, et al. Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. Int J Immunogenet 2005; 32:99-106.
96. Zhang YJ, Moore JP. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 1999; 73:3443-8.
97. Zhang YJ, Dragic T, Cao Y, et al. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998; 72:9337-44.
98. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4:350-3.
99. Rizzardi GP, Morawetz RA, Vicenzi E, et al. CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med 1998; 4: 252-3.
100. Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3:1160-2.
101. Eugen-Olsen J, Iversen AK, Benfield TL, Koppelhus U, Garred P. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:110-6.
102. Mariani R, Wong S, Mulder LC, et al. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol 1999; 73:2450-9.
103. Lee B, Doranz BJ, Rana S, et al. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998; 72:7450-8.
104. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279:389-93.
105. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene valiant in the clinical course of HIV-1 infection. Aids 1998; 12: F85-90.
106. Wang H, Li B, Xu L, et al. Genetic analysis of human immunodeficiency virus type 1 strains from AIDS patients in Shenzhen. Chin J Lab Med 2005; 28.
107. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-1815.
108. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002; 99:10002-7.
109. Liu XL, Wang FS, Jin L, Liu MX, Xu DZ. Preliminary study on the association of chemokine RANTES gene polymorphisms with HIV-1 infection in Chinese Han population. Zhonghua Liu Xing Bing Xue Za Zhi 2003; 24:971-5.
110. Zhao XY, Lee SS, Wong KH, et al. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. Eur J Immunogenet 2004; 31:179-83.
111. Aguado B, Campbell RD. Characterization of a human MHC class III region gene product with S-thioesterase activity. Biochem J 1999; 341 (Pt 3):679-89.
112. Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science 1996; 272:67-74.
113. Barber LD, Gillece-Castro B, Percival L, Li X, Clayberger C, Parham P. Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. Curr Biol 1995; 5:179-90.
114. Gao X, Nelson GW, Karacki P, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344:1668-75.
115. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296:1439-43.
116. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage [see comments]. Science 1999; 283:1748-1752.
117. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-51.
118. O'Brien SJ, Gao X and Carrington M. HLA, AIDS: a cautionary tale. Trends Mol Med 2001; 7:379-81.
119. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-34.
120. Xu MY, Hong KX, Deng XL, et al. Association of HLA-B alleles with human immunodeficiency virus type 1 infection in the Yi ethnic group in Sichuan province. Biomed Environ Sci 2004; 17:203-8.
121. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999; 285:1261-5.
122. Barratt-Boyes S, Watkins S, Finn O. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 1997; 158:4543-7.
123. Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances transinfection of T cells. Cell 2000; 100:587-97.
124. Pohlmann S, Baribaud F, Lee B, et al. DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus. J Virol 2001; 75:4664-72.
125. Bashirova AA, Geijtenbeek TBH, van Duijnhoven GCF, et al. A Dendritic Cell-specific Intercellular Adhesion Molecule 3-grabbing Nonintegrin (DC-SIGN)-related Protein Is Highly Expressed on Human Liver Sinusoidal Endothelial Cells and Promotes HIV-1 Infection. J Exp Med 2001; 193:671-78.
126. Pohlmann S, Soilleux EJ, Baribaud F, et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A 2001; 98:2670-5.
127. Liu H, Hladik F, Andrus T, et al. Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms. Eur J Hum Genet 2005; 13:707-15.
128. Soilleux EJ, Barten R, Trowsdale J. Cutting Edge: DC-SIGN; a Related Gene, DC-SIGNR; and CD23 Form a Cluster on 19p13. J Immunol 2000; 165:2937-42.
129. Mummidi S, Catano G, Lam L, et al. Extensive Repertoire of Membrane-bound and Soluble Dendritic Cell-specific ICAM-3-grabbing Nonintegrin 1 (DC-SIGN1) and DC-SIGN2 Isoforms. INTER-INDIVIDUAL VARIATION IN EXPRESSION OF DC-SIGN TRANSCRIPTS. J. Biol. Chem. 2001; 276:33196-212.
130. Liu HL, Carrington M, Wang CW, et al. Effects of Genetic Polymorphisms in the DC-SIGNR Repeat Region onHIV-1 Susceptibility. Journal of Infectious Disease 2005.
131. Martin MP, Lederman MM, Hutcheson HB, et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodefi-ciency virus type 1 infection. J Virol 2004; 78:14053-6.
132. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351:14-8.
133. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997; 61:1261-7.
134. Ansari-Lari MA, Liu XM, Metzker ME, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet 1997; 16:221-2.
135. Ma L, Dudoit Y, Tran T, et al. Biochemical and HIV-1 coreceptor properties of K26R, a new CCR5 Variant in China's Sichuan population. J Acquir Immune Defic Syndr 2005; 39:38-43.
136. Zhao XY, Lee SS, Wong KH, et al. Functional analysis of naturally occurring mutations in the open reading frame of CCR5 in HIV-infected Chinese patients and healthy controls. J Acquir Immune Defic Syndr 2005; 38:509-17.
137. Martin MP, Carrington M, Dean M, et al. CXCR4 polymorphisms and HIV-1 pathogenesis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:430.
138. Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 1998; 273:4754-60.